NCT07174687 - SGLT2 Inhibitors in Geographic Atrophy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

October 31, 2027

Study Completion Date

December 31, 2027

Conditions

Retinal DegenerationRetinal DiseasesEye DiseasesGeographic AtrophyPathological Conditions, Anatomical

Interventions

DRUG

Dapagliflozin

Dapagliflozin is an SGLT2 inhibitor used in diabetes, heart failure, and chronic kidney disease patients.

OTHER

Matching Placebo

Matching oral placebo to dapagliflozin

Trial Locations (1)

RECRUITING

Washington University, St Louis

All Listed Sponsors

lead

Washington University School of Medicine

OTHER